Advanced search
Start date

Role of cellular and extra-cellular PAR-4 expression in tumor formation and drug sensitivity

Grant number: 13/08110-0
Support type:Scholarships in Brazil - Doctorate (Direct)
Effective date (Start): July 01, 2013
Effective date (End): April 30, 2017
Field of knowledge:Biological Sciences - Genetics
Principal Investigator:Maria Aparecida Nagai
Grantee:Lourival Antunes de Oliveira Filho
Home Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil


The pro-apoptotic gene PAWR (PKC apoptosis regulator WT1, also known as PAR-4 Prostate apoptosis response-4) is known to selectively induce apoptosis in a variety of cancer cells. High levels of protein kinase A within cells and endoplasmic reticulum stress to PAR-4 confer the ability selectively to cancer, inducing apoptosis by both intrinsic and extrinsic mechanisms. Recently, studies have shown that systemic expression of PAR-4 confers resistance to the development of spontaneous tumors in mice. Furthermore, PAR-4 recombinant injected intravenously in mice inhibited tumor growth and metastasis formation. Currently, little is known regarding the role of PAR-4 in the tumorigenesis of breast cancer. Functional studies in vitro and in vivo PAR-4 in breast tumor cells are important for a better understanding of their role in the process of mammary tumorigenesis. In this project, using transgenic mouse models for the SAC domain of Par-4, we test the hypothesis that expression of SAC/PAR-4 the microenvironment and/or tumor cells can influence tumor development and the sensitivity of tumor cells to breast cancer chemotherapeutic agents. (AU)

Academic Publications
(References retrieved automatically from State of São Paulo Research Institutions)
FILHO, Lourival Antunes de Oliveira. Role of cellular and extra-cellular Par-4 expression in tumor formation and drug sensitivity. 2017. Doctoral Thesis - Universidade de São Paulo (USP). Faculdade de Medicina São Paulo.

Please report errors in scientific publications list by writing to: